4 Teams Advance to the George Shultz Innovation Fund Finals
The teams will pitch to the Innovation Fund Advisory Committee, which consists of advisors, entrepreneurs, and industry experts, during the finals event on Thursday, May 29, 2025.
staC12 is building an integrated diamond platform – thin-film single-crystal diamond bonded to a number of relevant materials, including silicon, sapphire, and fused silica – that enables the practical adoption of diamond in semiconductor and quantum applications.
CavilinQ is creating a fundamentally scalable quantum computing architecture based on precisely controlled arrays of neutral atoms interconnected via optical cavities.
Theta Neurotech is developing a near-invisible EEG patch that predicts and alerts patients of epileptic seizures before they occur.
PeptiForge // PeptiForge is creating a drug discovery platform that produces high-fidelity protein binders through a method that’s 50-times faster and 50-times less expensive than existing technologies.
To date, the Innovation Fund has invested in more than 90 companies. Notable companies launched with the fund’s support include ExplORer Surgical, acquired by Global Healthcare Exchange; Super.Tech, acquired by ColdQuanta; OrisDx, which won the 2022 New Venture Challenge; Flow Medical, which recently secured $5 million in seed funding; and Alnair Therapeutics, which closed an oversubscribed $1+ million pre-seed funding round.
The core mission of the Innovation Fund is to help scientific founders turn their innovations into ventures that advance cutting-edge technologies, generate significant financial returns, and create lasting impact for humankind.